Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Aptar Pharma Acquires Pulmotree, Expanding Growth Opportunities in Next-Generation ...

26 October 2026 · By · Wire by Fusion42

Published

26 October 2026

Topic

opportunities

◆ Sectors

Medtech

◆ Geography

Germany

◆ Source

Read at aptar.com →

◆ Verified

Fusion42 · 26 October 2026 · Fusion42 review

Aptar Pharma has acquired Pulmotree, a Munich-based company, to boost growth in pulmonary drug delivery using Pulmotree's Kolibri™ Non-Propellant Liquid Inhaler platform, enhancing delivery of complex molecules including biologics.

This Wire brief sits within Fusion42's coverage of Medtech, and 2 sources have reported it.

◆ ◆ The Wire takeaway

You can now access a proven non-propellant inhaler technology combined with top-notch formulation and regulatory support through Aptar. This acquisition opens new ways for you to develop and commercialise complex inhaled biologic therapies globally.

◆ Coverage

2 sources · 26 Oct 2026

◆ Related on Wire

◆ Topics

Medtechpulmonary-deliverypharma-acquisitionnon-propellant-inhalerbiologicsdrug-delivery